High-Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib-Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition

Overview

Journal Case Rep Hematol

Publisher Wiley

Specialty Hematology

Date 2024 Nov 25

PMID 39583986

Authors

Daniel James

Simone Green

Stefano Molica

David Allsup

Affiliations

Soon will be listed here.

Abstract

The coexistence of chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) in the same patient is exceedingly rare, with only a few cases reported in the literature. Here, we report a patient with CML who, having achieved a major molecular response with imatinib, subsequently developed CLL, which necessitated the concomitant administration of ibrutinib.

References

Lai M, Pampena R, Cornacchia L, Odorici G, Piccerillo A, Pellacani G . Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia: a systematic review of the literature. Int J Dermatol. 2021; 61(5):548-557. PMC: 9290486. DOI: 10.1111/ijd.15813. View

Rahman K, George S, Mangal S, Mehta A . Simultaneous occurrence of chronic myeloid leukemia and chronic lymphocytic leukemia: report of an unusual case. Indian J Pathol Microbiol. 2014; 56(4):453-6. DOI: 10.4103/0377-4929.125369. View

Shea L, Mikhail F, Forero-Torres A, Davis R . Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia. Clin Case Rep. 2017; 5(6):899-901. PMC: 5458012. DOI: 10.1002/ccr3.974. View

de Zwart L, Snoeys J, de Jong J, Sukbuntherng J, Mannaert E, Monshouwer M . Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling. Clin Pharmacol Ther. 2016; 100(5):548-557. DOI: 10.1002/cpt.419. View

Lin Q, Mao L, Shao L, Zhu L, Han Q, Zhu H . Global, Regional, and National Burden of Chronic Myeloid Leukemia, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Front Oncol. 2021; 10:580759. PMC: 7770240. DOI: 10.3389/fonc.2020.580759. View

Bhagavathi S, Borromeo V, Desai H, Crisan D . Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia. Ann Clin Lab Sci. 2008; 38(4):405-9. View

Przespolewski E, Baron J, Kashef F, Fu K, Jani Sait S, Hernandez-Ilizaliturri F . Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report. J Natl Compr Canc Netw. 2023; 21(2):102-107. DOI: 10.6004/jnccn.2022.7069. View

DArena G, Gemei M, Luciano L, DAuria F, Deaglio S, Statuto T . Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?. J Clin Oncol. 2012; 30(32):e327-30. DOI: 10.1200/JCO.2012.42.6767. View

Appel S, Balabanov S, Brummendorf T, Brossart P . Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells. 2005; 23(8):1082-8. DOI: 10.1634/stemcells.2005-0069. View

10.

Filppula A, Laitila J, Neuvonen P, Backman J . Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2011; 165(8):2787-98. PMC: 3423228. DOI: 10.1111/j.1476-5381.2011.01732.x. View

11.

Hasford J, Pfirrmann M, Hehlmann R, Allan N, Baccarani M, Kluin-Nelemans J . A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998; 90(11):850-8. DOI: 10.1093/jnci/90.11.850. View

12.

Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H . iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018; 131(25):2745-2760. DOI: 10.1182/blood-2017-09-806398. View

13.

Ou Y, Long Y, Ji L, Zhan Y, Qiao T, Wang X . Trends in Disease Burden of Chronic Lymphocytic Leukemia at the Global, Regional, and National Levels From 1990 to 2019, and Projections Until 2030: A Population-Based Epidemiologic Study. Front Oncol. 2022; 12:840616. PMC: 8961301. DOI: 10.3389/fonc.2022.840616. View

14.

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

15.

Sokal J, Cox E, Baccarani M, Tura S, Gomez G, Robertson J . Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984; 63(4):789-99. View

16.

Chow K, Nowak D, Hofmann W, Schneider B, Hofmann W . Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4. Leukemia. 2005; 19(6):1103-5. DOI: 10.1038/sj.leu.2403739. View

17.

Miranda M, Lauseker M, Kraus M, Proetel U, Hanfstein B, Fabarius A . Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia. 2016; 30(6):1255-62. PMC: 4895174. DOI: 10.1038/leu.2016.20. View